Yin, C Cameron <br/><br/>
t(3;21)(q26;q22) in myeloid leukemia: an aggressive syndrome of blast transformation associated with hydroxyurea or antimetabolite therapy.  [electronic resource] 

 -  Cancer  Apr 2006 
 - 1730-8 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0008-543X 
<br/><br/><label>Standard No.: </label>10.1002/cncr.21797  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antimetabolites, Antineoplastic--adverse effects<br/>Antineoplastic Agents--adverse effects<br/>Bone Marrow--pathology<br/>Chromosomes, Human, Pair 21--drug effects<br/>Chromosomes, Human, Pair 3--drug effects<br/>Core Binding Factor Alpha 2 Subunit--genetics<br/>DNA-Binding Proteins--genetics<br/>Female<br/>Humans<br/>Hydroxyurea--adverse effects<br/>Leukemia, Myeloid--chemically induced<br/>Lymphocyte Activation--drug effects<br/>MDS1 and EVI1 Complex Locus Protein<br/>Male<br/>Middle Aged<br/>Myeloproliferative Disorders--drug therapy<br/>Neoplasm Proteins--genetics<br/>Oncogene Proteins, Fusion--analysis<br/>Proto-Oncogenes--genetics<br/>Transcription Factors--genetics<br/>Translocation, Genetic--drug effects